In the rollercoaster realm of financial markets, investors were greeted with a pleasant surprise as shares of Chemours Co (Symbol: CC) danced above the average analyst 12-month target price of $28.00, fetching $28.37 per share. When a stock hits this coveted target, analysts find themselves at a crossroads: downgrade based on valuation, or recalibrate their sights to aim higher. Their decision often hinges on the company’s underlying business trajectory that propels its stock price upwards.
Within the Zacks coverage universe, eight diverse analyst targets contribute to the average for Chemours Co. Yet, let’s not get too caught up in averages – they are merely a mathematical construct. Some analysts set their sights below the average, with a lone voice foreseeing a price of $19.00. On the flip side, another analyst boldly predicts a lofty target of $40.00. The standard deviation paints a picture of $6.611.
The significance of examining the average CC price target lies in tapping into a collective “wisdom of crowds” phenomenon, amalgamating insights from various expert minds. With CC surpassing the $28.00/share average target price, investors are handed a golden opportunity to reevaluate the company. Now, they must ponder: Is $28.00 merely a stepping stone towards an even loftier target, or has the valuation reached a point where securing gains is prudent?
| Recent CC Analyst Ratings Breakdown | ||||
|---|---|---|---|---|
| » | Current | 1 Month Ago | 2 Month Ago | 3 Month Ago |
| Strong buy ratings: | 0 | 2 | 2 | 2 |
| Buy ratings: | 1 | 1 | 1 | 1 |
| Hold ratings: | 6 | 5 | 5 | 5 |
| Sell ratings: | 0 | 0 | 0 | 0 |
| Strong sell ratings: | 1 | 0 | 0 | 0 |
| Average rating: | 3.13 | 2.38 | 2.38 | 2.38 |
The average rating, as depicted in the table, ranges from 1 (Strong Buy) to 5 (Strong Sell). The data utilized in this article is sourced from Zacks Investment Research via Quandl.com. Access the latest Zacks research report on CC — FREE.
Check out the 10 ETFs With Most Upside To Analyst Targets »
Also see:
• CWEN Options Chain
• Funds Holding WNW
• Funds Holding BOCH
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
